Accutane Risk Management Program Loosens Restrictions
This article was originally published in The Pink Sheet Daily
Males and females of non-child bearing potential – over half the iPLEDGE participants – can now fill their scripts even if they miss the seven-day window.
You may also be interested in...
FDA confirmed that it would not delay the March 1 implementation of the isotretinoin risk management program.
Study everything together and a scale-up manufacturing after preliminary efficacy results, former FDA commissioners Gottlieb and McClellan and their coauthors recommend in a pair of white papers on how the US should respond to the coronavirus pandemic.
Pink Sheet Podcast: Understanding the White House Coronavirus Treatment Announcement, US FDA Postpones Domestic Inspections, Biologics Transition Day Arrives
Pink Sheet editor and reporters discuss the pending trials of chloroquine for use against coronavirus, expanded access for remdesivir, and the official move of several biologics from regulation as drugs to regulation as biologics.